HIGH-DOSE FOSTER BECLOMETASONE DIPROPIONATE/FORMOTEROL FUMARATE IN FIXED-DOSE COMBINATION FOR THE TREATMENT OF ASTHMA

Abstract

The high-strength formulation of extrafine beclometasone dipropionate/formoterol fumarate (BDP/ Form) 200/6 μg has been developed to step up inhaled corticosteroid treatment, without increasing the dose of the bronchodilator, in patients who are not controlled with previous therapies. Two clinical studies have evaluated efficacy of high-strength BDP/Form as compared with another high-dose fixed combination and BDP monotherapy. Overall,  data show that BDP/Form 200/6 μg improves lung function and has beneficial effects on symptoms, use of rescue medication and asthma control, with an acceptable safety profile comparable with that of high-dose fluticasone propionate/salmeterol. Therefore, BDP/Form 200/6 μg could be considered as an effective and safe treatment for patients with asthma who are not adequately controlled with high doses of inhaled corticosteroid monotherapy or medium doses of inhaled corticosteroid/long-acting β2-agonist combinations.